Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.Hosp Israelita Albert Einstein, Programa Posgrad, Sao Paulo, SP, BrazilUniv Fed Sao Paulo UNIFESP, Movement Disorders Dept Neurol, Sao Paulo, SP, BrazilUniv Fed Sao Paulo UNIFESP, Sao Paulo, SP, BrazilHosp Israelita Albert Einstein, Neurol Program, Sao Paulo, SP, BrazilMovement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilWeb of Scienc

High efficiency blue organic light-emitting diodes with below-bandgap electroluminescence

Blue organic light-emitting diodes require high triplet interlayer materials, which induce large energetic barriers at the interfaces resulting in high device voltages and reduced efficiencies. Here, we alleviate this issue by designing a low triplet energy hole transporting interlayer with high mobility, combined with an interface exciplex that confines excitons at the emissive layer/electron transporting material interface. As a result, blue thermally activated delay fluorescent organic light emitting diodes with a below-bandgap turn-on voltage of 2.5 V and an external quantum efficiency of 41.2% were successfully fabricated. These devices also showed suppressed efficiency roll-off maintaining an EQE of 34.8% at 1000 cd m-2. Our approach paves the way for further progress through exploring alternative device engineering approaches instead of only focusing on the demanding synthesis of organic compounds with complex structures

Observation of large Rashba spin–orbit coupling at room temperature in compositionally engineered perovskite single crystals and application in high performance photodetectors

This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this recordIndirect absorption extended below the direct transition edge and increase in carrier lifetime derived from Rashba spin-orbit coupling may advance the optoelectronic applications of metal halide perovskites. Spin-orbit coupling in halide perovskites is due to the presence of heavy elements in their structure. However, when these materials lack an inversion symmetry, for example by the application of strain, spin-orbit coupling becomes odd in the electron’s momentum giving rise to a splitting in the electronic energy bands. Here we report on the observation of a large Rashba splitting of 117 meV at room temperature through a facile compositional engineering approach in halide perovskite single crystals, as predicted by relativistic first-principles calculations. Partial substitution of organic cations by rubidium ions in single crystals induces significant indirect absorption and dual emission as a result of a large Rashba splitting. We measured significant magneto-photocurrent, magneto-electroluminescence and magneto-photoluminescence responses in perovskite single crystal devices and thin films. They originate from the significant spin-momentum locking that leads to different precession frequencies of their respective spins about the applied magnetic field. A hybrid perovskite single crystal photodetector achieved record figures of merit, including detectivity of more than 1.3×1018 Jones which represents a three orders of magnitude improvement compared to the to date record. These findings show that facile compositional engineering of perovskite single crystals holds great promise for further advancing the optoelectronic properties of existing materials.European Regional Development Fund (ERDF)European Union Horizon 2020Ministero dell’Istruzione dell’Universitàe della Ricerca (MIUR)Università degli Studi di PerugiaCNPq, Brazi

– Cardiodesfibrilador Implantável – Infecção em DCEI – Papel dos Fármacos Antiarrítmicos – Direção Veicular em Portadores de DCEI

Desde o primeiro implante, em 1980, até os dias atuais, ocorreram importantes avanços no cardiodesfibrilador implantável (CDI), tanto no tamanho como nas funções e programações. Atualmente esses dispositivos dispõem de terapia antitaquicardia (ATP), cardioversão com baixa energia, desfibrilação com alta energia e função antibradicardia de backup. Diversos estudos de grande porte demonstraram que o CDI trata efetivamente os eventos de taquicardia ventricular e fibrilação ventricular, reduzindo a mortalidade quando comparado com fármacos antiarrítmicos isoladamente.[...

– Implante de Marcapasso nas Bradicardias e em Outras Situações Especiais – Estratificação de Risco de Morte Súbita na Cardiomiopatia Chagásica

A frequência cardíaca normal varia de 60 bpm a 100 bpm. Ritmos com frequência cardíaca < 60 bpm são definidos como bradicardia, que pode ser assintomática ou sintomática. As bradicardias sintomáticas têm características clínicas comuns, marcadas, sobretudo, pela síndrome do baixo fluxo cerebral e/ou sistêmico, cujos sintomas mais comuns são tontura, pré-síncope, síncope, fadiga, dispneia de esforço e bradipsiquismo, sendo comumente ocasionadas por doença do nó sinusal e bloqueio atrioventricular. As assintomáticas, geralmente, são de causas fisiológicas, representadas por bradicardia sinusal e ritmos de escape da junção atrioventricular

– Terapia de Ressincronização Cardíaca

A insuficiência cardíaca é uma significante causa de morbidade e mortalidade em todo o mundo, com prevalência de 2,4% dos adultos 1 (A). Embora a sobrevivência após o diagnóstico de insuficiência cardíaca tenha melhorado nas duas últimas décadas, as taxas de morte e hospitalização por insuficiência cardíaca permanecem altas e aproximadamente 50% dos pacientes morrem dentro de 5 anos do diagnóstico 1 (A). Adicionalmente, a despeito do tratamento medicamentoso otimizado, muitos pacientes com insuficiência cardíaca permanecem sintomáticos e com redução da qualidade de vida 2 (D)